霍奇金淋巴瘤(Hodgkn’s lymphoma,HL)是1种临床常见的可被治愈的恶性肿瘤,是现代肿瘤学治疗的成功典范,在诊治方面逐渐形成一些相对成熟的规范和常规,如以BEACOPP或AB-VD方案为金标准的一线规范化治疗方案,虽然可以治愈超过70%的患者,但仍有15%～20%的Ⅰ～Ⅱ期HL患者、35%～40%Ⅲ～Ⅳ期患者一线治疗后会复发[1]。有证据显示[2]复发 Hodgkn’s lymphoma (HL) is a common and clinically curable malignant tumor. It is a successful example of modern oncology treatment. There are some mature norms and conventions in the field of diagnosis and treatment, such as BEACOPP or AB-VD regimen is the gold standard first-line standardized regimen. Although more than 70% of patients can be cured, 15% to 20% of patients with stage Ⅰ-Ⅱ HL and 35% -40% of patients with stage Ⅲ-Ⅳ are still treated with first- After the recurrence [1]. There is evidence that relapse [2]